Viruses · 2025
Evidence Generation for a Host-Response Biosignature of Respiratory Disease.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dooley Kelly E, Morimoto Michael, Kaszuba Piotr, Krasne Margaret, Liu Gigi, Fuchs Edward, Rexelius Peter, Swan Jerry, Krawiec Krzysztof, Hammond Kevin, Ray Stuart C, Hafen Ryan, Schuh Andreas, Jumbe Nelson L Shasha
Аннотация
BACKGROUND: In just twenty years, three dangerous human coronaviruses-SARS-CoV, MERS-CoV, and SARS-CoV-2 have exposed critical gaps in early detection of emerging viral threats. Current diagnostics remain pathogen-focused, often missing the earliest phase of infection. A virus-agnostic, host-based diagnostic capable of detecting responses to viral intrusion is urgently needed.
METHODS: We hypothesized that the lungs act as biomechanical instruments, with infection altering tissue tension, wave propagation, and flow dynamics in ways detectable through subaudible vibroacoustic signals. In a matched case-control study, we enrolled 19 RT-PCR-confirmed COVID-19 inpatients and 16 matched controls across two Johns Hopkins hospitals. Multimodal data were collected, including passive vibroacoustic auscultation, lung ultrasound, peak expiratory flow, and laboratory markers. Machine learning models were trained to identify host-response biosignatures from anterior chest recordings.
RESULTS: 19 COVID-19 inpatients and 16 matched controls (mean BMI 32.4 kg/m2, mean age 48.6 years) were successfully enrolled to the study. The top-performing, unoptimized, vibroacoustic-only model achieved an AUC of 0.84 (95% CI: 0.67-0.92). The host-covariate optimized model achieved an AUC of 1.0 (95% CI: 0.94-1.0), with 100% sensitivity (95% CI: 82-100%) and 99.6% specificity (95% CI: 85-100%). Vibroacoustic data from the anterior chest alone reliably distinguished COVID-19 cases from controls.
CONCLUSIONS: This proof-of-concept study demonstrates that passive, noninvasive vibroacoustic biosignatures can detect host response to viral infection in a hospitalized population and supports further testing of this modality in broader populations. These findings support the development of scalable, host-based diagnostics to enable early, agnostic detection of future pandemic threats (ClinicalTrials.gov number: NCT04556149).
METHODS: We hypothesized that the lungs act as biomechanical instruments, with infection altering tissue tension, wave propagation, and flow dynamics in ways detectable through subaudible vibroacoustic signals. In a matched case-control study, we enrolled 19 RT-PCR-confirmed COVID-19 inpatients and 16 matched controls across two Johns Hopkins hospitals. Multimodal data were collected, including passive vibroacoustic auscultation, lung ultrasound, peak expiratory flow, and laboratory markers. Machine learning models were trained to identify host-response biosignatures from anterior chest recordings.
RESULTS: 19 COVID-19 inpatients and 16 matched controls (mean BMI 32.4 kg/m2, mean age 48.6 years) were successfully enrolled to the study. The top-performing, unoptimized, vibroacoustic-only model achieved an AUC of 0.84 (95% CI: 0.67-0.92). The host-covariate optimized model achieved an AUC of 1.0 (95% CI: 0.94-1.0), with 100% sensitivity (95% CI: 82-100%) and 99.6% specificity (95% CI: 85-100%). Vibroacoustic data from the anterior chest alone reliably distinguished COVID-19 cases from controls.
CONCLUSIONS: This proof-of-concept study demonstrates that passive, noninvasive vibroacoustic biosignatures can detect host response to viral infection in a hospitalized population and supports further testing of this modality in broader populations. These findings support the development of scalable, host-based diagnostics to enable early, agnostic detection of future pandemic threats (ClinicalTrials.gov number: NCT04556149).